logo.png
Adhera Receives European Patent Covering MLR-1019 and Derivatives for Treating Dyskinesias
04 oct. 2021 09h15 HE | Adhera Therapeutics, Inc.
Baton Rouge, LA, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that a new...